These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 27483245)

  • 21. Incretin-based therapies and cardiovascular risk.
    Mannucci E; Dicembrini I
    Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
    Balakumar P; Dhanaraj SA
    Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.
    Panchapakesan U; Mather A; Pollock C
    Clin Sci (Lond); 2013 Jan; 124(1):17-26. PubMed ID: 22963445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incretin-based therapies, glucometabolic health and endovascular inflammation.
    Rizzo M; Nikolic D; Banach M; Patti AM; Montalto G; Rizvi AA
    Curr Pharm Des; 2014; 20(31):4953-60. PubMed ID: 24320037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond glycemic control: cardiovascular effects of incretin-based therapies.
    Angeli FS; Shannon RP
    Front Horm Res; 2014; 43():144-57. PubMed ID: 24943305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Updates of incretin-related drugs for the treatment of type 2 diabetes.
    Araki H; Matsumura T; Furukawa N; Araki E
    J Diabetes Investig; 2023 Feb; 14(2):189-192. PubMed ID: 36373430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Incretin-Based Therapies on Diabetic Microvascular Complications.
    Kang YM; Jung CH
    Endocrinol Metab (Seoul); 2017 Sep; 32(3):316-325. PubMed ID: 28956360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2017 May; 127():224-237. PubMed ID: 28402902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiology and pathophysiology of incretins in the kidney.
    von Websky K; Reichetzeder C; Hocher B
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?
    Nauck M; Smith U
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):513-23. PubMed ID: 19748068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes.
    Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
    Life Sci; 2020 Jan; 241():117152. PubMed ID: 31837333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incretins: the novel therapy of type 2 diabetes.
    Thongtang N; Sriwijitkamol A
    J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incretins: Beyond type 2 diabetes.
    Dandona P; Ghanim H; Chaudhuri A
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():59-67. PubMed ID: 29364583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood pressure-lowering effects of incretin-based diabetes therapies.
    Lovshin JA; Zinman B
    Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.